Published in Rev Inst Med Trop Sao Paulo on January 05, 1973
Interspecific competition during transmission of two sympatric malaria parasite species to the mosquito vector. Proc Biol Sci (2002) 0.93
Chickens treated with a nitric oxide inhibitor became more resistant to Plasmodium gallinaceum infection due to reduced anemia, thrombocytopenia and inflammation. Vet Res (2013) 0.75
Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc Natl Acad Sci U S A (1996) 2.35
Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol (1976) 2.20
Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol (1982) 2.10
Depletion of T and B lymphocytes during malarial infections. Cell Immunol (1974) 1.65
American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull World Health Organ (2000) 1.51
Virus-expressed, recombinant single-chain antibody blocks sporozoite infection of salivary glands in Plasmodium gallinaceum-infected Aedes aegypti. Am J Trop Med Hyg (2000) 1.51
Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol (1979) 1.44
Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's disease. Trans R Soc Trop Med Hyg (1982) 1.41
Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg (1993) 1.38
Antimalarial activity of crude extracts from Brazilian plants studied in vivo in Plasmodium berghei-infected mice and in vitro against Plasmodium falciparum in culture. Braz J Med Biol Res (1991) 1.36
Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol Biochem Parasitol (1992) 1.27
Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection. Clin Exp Immunol (1985) 1.23
Potential antimalarials from Nigerian plants: a review. J Ethnopharmacol (2010) 1.22
Antimalarial activity of extracts and fractions from Bidens pilosa and other Bidens species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds. J Ethnopharmacol (1997) 1.22
Cross-reactivity between antibodies in the sera of individuals with leishmaniasis, toxoplasmosis, and Chagas' disease and antigens of the blood-stage forms of Plasmodium falciparum determined by indirect immunofluorescence. Am J Trop Med Hyg (1995) 1.21
Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal (1993) 1.16
Developmentally regulated infectivity of malaria sporozoites for mosquito salivary glands and the vertebrate host. J Exp Med (1992) 1.14
Antimalarial activity of Cinchona-like plants used to treat fever and malaria in Brazil. J Ethnopharmacol (2003) 1.08
[Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease]. Rev Soc Bras Med Trop (1994) 1.07
Antiplasmodial triterpene from Vernonia brasiliana. Planta Med (1997) 1.05
Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J Clin Microbiol (1995) 1.04
Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol (1985) 1.01
Controlling malaria transmission with genetically-engineered, Plasmodium-resistant mosquitoes: milestones in a model system. Parassitologia (1999) 1.00
Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission. Scand J Immunol (2008) 0.99
Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in patients with treated or untreated Chagas' disease. J Infect Dis (2000) 0.99
Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas' disease. Infect Immun (1994) 0.97
New evidences of antimalarial activity of Bidens pilosa roots extract correlated with polyacetylene and flavonoids. J Ethnopharmacol (2004) 0.96
Survey of medicinal plants used as antimalarials in the Amazon. J Ethnopharmacol (1992) 0.94
Plasmodium gallinaceum: antibodies to circumsporozoite protein prevent sporozoites from invading the salivary glands of Aedes aegypti. Exp Parasitol (1992) 0.91
The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today (2000) 0.91
Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies. Parasite Immunol (1985) 0.90
Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. J Eukaryot Microbiol (1996) 0.90
Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Am J Trop Med Hyg (1993) 0.89
Persistence of humoral response against sporozoite and blood-stage malaria antigens 7 years after a brief exposure to Plasmodium vivax. J Infect Dis (1998) 0.88
[Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis features (1989-1995)]. Rev Soc Bras Med Trop (2001) 0.87
Exacerbation of experimental Trypanosoma cruzi infection in mice by concomitant malaria. J Protozool (1977) 0.86
In vitro activity of natural and synthetic naphthoquinones against erythrocytic stages of Plasmodium falciparum. Braz J Med Biol Res (1988) 0.86
Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade. Clin Exp Immunol (1985) 0.85
Ampelozyziphus amazonicus Ducke (Rhamnaceae), a medicinal plant used to prevent malaria in the Amazon Region, hampers the development of Plasmodium berghei sporozoites. Int J Parasitol (2008) 0.84
Differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp. using ELISA with a recombinant antigen (rTc24). Mem Inst Oswaldo Cruz (1998) 0.84
Complement alterations in rodent malaria. Am J Trop Med Hyg (1976) 0.84
Human antibody responses to Trypanosoma cruzi 70-kD heat-shock proteins. Am J Trop Med Hyg (1998) 0.84
Evaluation of the antiplasmodial and cytotoxicity potentials of husk fiber extracts from Cocos nucifera, a medicinal plant used in Nigeria to treat human malaria. Hum Exp Toxicol (2012) 0.83
Antimalarial chemotherapy with natural products and chemically defined molecules. Mem Inst Oswaldo Cruz (1991) 0.83
Anti-Trypanosoma cruzi and anti-laminin antibodies in chagasic patients after specific treatment. J Clin Microbiol (1988) 0.82
In vitro development of exoerythrocytic forms of Plasmodium gallinaceum sporozoites in avian macrophages. J Protozool (1991) 0.82
Infectivity of Plasmodium gallinaceum sporozoites from oocysts. J Protozool (1980) 0.81
Hemocultures from chronic Chagasic patients using EDTA or heparin as anticoagulants. Braz J Med Biol Res (1989) 0.80
Factors influencing the development of Plasmodium gallinaceum in Aedes fluviatilis. Mem Inst Oswaldo Cruz (1984) 0.80
The immunodominant surface antigen of Plasmodium gallinaceum is present in both the salivary gland and oocyst sporozoites. Braz J Med Biol Res (1990) 0.80
Comparative study of experimental infections in mice inoculated with normal and chloroquine-resistant strains of Plasmodium berghei. Rev Inst Med Trop Sao Paulo (1969) 0.79
Cellular responses to Plasmodium falciparum major surface antigens and their relationship to human activities associated with malaria transmission. Am J Trop Med Hyg (1999) 0.79
Trypanosomatid isolates from Honduras: differentiation between Trypanosoma cruzi and Trypanosoma rangeli. Am J Trop Med Hyg (1991) 0.79
[Soluble antigens released by Trypanosoma cruzi trypomastigotes used in ELISA to detect cure in chagasic patients following specific treatment]. Rev Soc Bras Med Trop (1995) 0.79
EVI antibodies in patients with Chagas' disease: relationship with anti-Trypanosoma cruzi immunoglobulins and effects of specific treatment. Mem Inst Oswaldo Cruz (1986) 0.78
Exoerythrocytic development of Plasmodium gallinaceum sporozoites in a chicken fibroblast cell line and inhibition of the cell invasion by specific anti-sporozoite monoclonal antibodies. J Eukaryot Microbiol (1993) 0.78
Aedes fluviatilis (Lutz), a new experimental host for Plasmodium gallinaceum brumpt. J Parasitol (1978) 0.78
A method for screening drugs against the liver stages of malaria using Plasmodium gallinaceum and Aedes mosquitos. Braz J Med Biol Res (1992) 0.78
Effect of protective and non-protective antibodies in the phagocytosis rate of Trypanosoma cruzi blood forms by mouse peritoneal macrophages. Parasite Immunol (1987) 0.78
Antimalarial activity of natural, racemic and unnatural dihydroquinine, dihydroquinidine and their various racemic analogs in mice infected with Plasmodium berghei. Experientia (1971) 0.77
Anti-plasmodial and anti-trypanosomal activity of synthetic naphtho[2,3-b]thiopen-4,9-quinones. Bioorg Med Chem (1997) 0.77
Cross-reactive cellular immune response to circumsporozoite proteins of Plasmodium vivax and P. falciparum in malaria-exposed individuals. Parasite Immunol (1997) 0.77
Common epitopes in the circumsporozoite proteins of Plasmodium berghei and Plasmodium gallinaceum identified by monoclonal antibodies to the P. gallinaceum circumsporozoite protein. J Eukaryot Microbiol (1993) 0.77
Antimalarial Activity of Cocos nucifera Husk Fibre: Further Studies. Evid Based Complement Alternat Med (2013) 0.77
Which routes do Plasmodium sporozoites use for successful infections of vertebrates? Infect Immun (2000) 0.76
Evaluation of antimalarial and fluoroquinolone combinations against Plasmodium falciparum in vitro. Int J Antimicrob Agents (2006) 0.75
Refractoriness of Callithrix penicillata red blood cells to Plasmodium falciparum in vivo and in vitro. J Parasitol (1988) 0.75
The effect of reinoculation with trypomastigotes on the level of protective antibodies in mice chronically infected with T. cruzi. Braz J Med Biol Res (1990) 0.75
Experimental vaccination of chicks with Plasmodium gallinaceum sporozoites. I. Circumsporozoite proteins are expressed by sporozoites recovered from both salivary glands and midguts of mosquitoes. J Protozool (1987) 0.75
Plasmodium vivax sporozoite antibodies in individuals exposed during a single malaria outbreak in a non-endemic area. Am J Trop Med Hyg (1991) 0.75
Therapeutic activity of some sulfonamide compounds on normal and chloroquine-resistant strains of Plasmodium berghei. Rev Inst Med Trop Sao Paulo (1969) 0.75
Experimental infections of simians with human malaria: attempts to infect Callithrix penicillata with Plasmodium falciparum. Parassitologia (1989) 0.75
Pedunculate oocysts in a Brazilian strain of Plasmodium juxtanucleare. J Parasitol (1972) 0.75
Antimalarial activity of racemic 3-epidihydroquinine, 3-epidihydroquinidine and their various racemic analogs in mice infected with Plasmodium berghei. Experientia (1973) 0.75
Effects of levamisole on experimental infections by Plasmodium berghei in mice. Rev Soc Bras Med Trop (1989) 0.75
Multifocal demyelinative lesions of peripheral nerves in experimental chronic Chagas's disease. Trans R Soc Trop Med Hyg (1981) 0.75
[Preparation and biological trials of antimalarial sulfa embonates]. Rev Farm Bioquim Univ Sao Paulo (1976) 0.75
Antimalarial activity of saccharidic polymers of dapsone and sulfadimethoxine. Chemotherapy (1978) 0.75